Developments in the management of all stages of prostate cancer are taking place on a regular basis. New biomarkers and evolving insight into genetic testing are giving guidance in prostate cancer decision making including treatment choices. PET scans have not been widely applied to prostate cancer, but newer agents are making this a more useful imaging approach. Biomarkers, genetics, PET imaging and new medications are the focus of this talk.
Continuing Education Instructions and Disclosure Information:
Contact hours available until 4/18/23.
Requirements for Successful Completion: Complete the learning activity in its entirety and complete the online nursing continuing professional development evaluation. You will be able to print your NCPD certificate at any time after you complete the evaluation.
Faculty, Planners, and Speakers Conflict of Interest Disclosure:
Planning Committee Disclosures: Julie A. Starr, PhD, APRN – Consultant for The Prometheus Group
There are no other Planning Committee disclosures to declare.
Speakers Conflict of Interest Disclosure: There are no speaker disclosures to declare.
Commercial Support and Sponsorship: No commercial support or sponsorship declared.
Accreditation Statement: The Society of Urologic Nurses and Associates (SUNA) is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
SUNA accreditation is reciprocal in the states and specialty organizations that recognize the ANCC-COA accreditation process. SUNA is also an approved provider of continuing nursing education by the California Board of Registered Nursing, Provider Number CEP 5556. Accreditation and approved provider status of NCPD does not imply ANCC-COA approval or endorsement of any product, advertising, or educational content. SUNA urges all participants to be aware of the CE requirements for re-licensure in the states in which they hold a license.
Learning Outcome: After completing this education activity, the learner will be knowledgeable about new diagnostics and treatment modalities for advanced prostate cancer.